Diadema Partners’s Viridian Therapeutics VRDN Stock Holding History

Diadema Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84M	Buy	+100,000	New	+$1.61M	0.23%	82
2026 Q1	–	Sell	-21,114	Closed	-$657K	–	209
2025 Q4	$657K	Buy	+21,114	New	+$579K	0.11%	104
2025 Q3	–	Sell	-122,061	Closed	-$1.71M	–	167
2025 Q2	$1.71M	Sell	122,061 -40,002	-25%	-$543K	0.52%	48
2025 Q1	$2.18M	Buy	162,063 +112,585	+228%	+$1.92M	0.57%	40
2024 Q4	$948K	Buy	+49,478	New	+$1.08M	0.41%	53

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Diadema Partners's VRDN Position: Q2 2026 in Review

Diadema Partners opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 100,000 shares worth $1.84M. The stake represents 0.23% of the portfolio and ranks #82 among its holdings. This is a return to the name: Diadema Partners previously reported a position in VRDN as recently as Q4 2025.

Diadema Partners first reported a position in VRDN in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.18M in Q1 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Diadema Partners held 100,000 shares of Viridian Therapeutics worth $1.84M as of Q2 2026.
Viridian Therapeutics was a new Diadema Partners position in Q2 2026.
Viridian Therapeutics made up 0.23% of Diadema Partners's portfolio in Q2 2026, its #82 holding.
Diadema Partners first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 5 quarters since.
Diadema Partners's Viridian Therapeutics position peaked at $2.18M in Q1 2025.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.